Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
(NASDAQ:CMPX), Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival (PFS) are expected in late Q1 2026. A new response in a third indication has […]